吡嗪-2-甲酰氯 - CAS号 19847-10-0

物化性质

熔点：

41°C
沸点：

214.5±20.0 °C(Predicted)
密度：

1.393±0.06 g/cm3(Predicted)
稳定性/保质期：

如果按照规则使用和储存，则不会分解。应避免接触氧化物、水分和碱。

计算性质

辛醇/水分配系数(LogP)：

1
重原子数：

9
可旋转键数：

1
环数：

1.0
sp3杂化的碳原子比例：

0.0
拓扑面积：

42.8
氢给体数：

0
氢受体数：

3

安全信息

危险等级：

8
安全说明：

S26,S36/37/39,S45
危险类别码：

R34
海关编码：

2933990090
危险品标志：

C
储存条件：

在干性保护气体中处理，并将产品存放在密封容器中，置于阴凉、干燥处保存。

SDS

SDS：708a2d4a641f5bf19e5cb6e0d7d63809

查看

Name:	2-Pyrazinecarbonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	19847-10-0

Section 1 - Chemical Product MSDS Name:2-Pyrazinecarbonyl chloride 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
19847-10-0	2-Pyrazinecarbonyl chloride	97%	243-367-4

Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19847-10-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 40.9 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H3ClN2O
Molecular Weight: 142.55

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19847-10-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Pyrazinecarbonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 19847-10-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19847-10-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19847-10-0 is not listed on the TSCA inventory.
It is for research and development use only.

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

作为反应物：

描述：

吡嗪-2-甲酰氯在 palladium dihydroxide 盐酸、氢气、 (1S)-(+)-10-camphorsulfonic acid 、三乙胺、异丙醇作用下，生成茚地那韦

参考文献：

名称：

手性非外消旋酰胺烯酸酯与（S）-缩水甘油基甲苯磺酸酯的高度非对映选择性反应。口服活性HIV-1蛋白酶抑制剂L-735,524的合成

摘要：

手性酰胺烯酸酯Li-1与（S）-缩水甘油基甲苯磺酸酯11的反应以高非对映体选择性得到环氧化物3，产率为72％。环氧化物3以71％的分离产率转化为口服活性的HIV-1蛋白酶抑制剂L-735,524。

DOI：

10.1016/s0040-4039(00)75787-x
作为产物：

描述：

2-甲酸吡嗪在氯化亚砜作用下，以苯为溶剂，生成吡嗪-2-甲酰氯

参考文献：

名称：

新型嵌合支架可扩展受体空间的探索：广泛筛选的混合β-d-葡萄糖-苯并二氮杂卓结构。酰胺烷基化对环化反应过程的影响

摘要：

设计，合成并功能化了新的分子平台，该平台是两个支架（β- d-葡萄糖和苯并二氮杂hybrid）的杂交体，每个支架都可以结合几种蛋白质，可以用作广泛生物学筛选的探针。在这里，我们描述了这些新型嵌合支架的合成和化学性质。尝试将官能化的类似物（-）- 96和（-）- 97环化，得到相应的二聚体（-）- 98和（-）- 99在各种反应条件下，甚至在浓度仅为0.001 N的情况下也是如此。考虑到影响酰胺键构象的因素及其对环化反应的影响，我们使酰胺键烷基化。如所预期的，N-甲基衍生物（-）- 110的环化仅提供了单分子环化产物（+）- 111。这些化合物现在才进行广泛的筛选，因此目前代表着“勘探库”。

DOI：

10.1021/jo0352068
作为试剂：

描述：

2-甲酸吡嗪、氯化亚砜在吡嗪-2-甲酰氯作用下，以苯为溶剂，反应 2.0h，生成吡嗪-2-甲酰氯

参考文献：

名称：

Pyrazinoic acid esters as anti-mycobacterium avium agents

摘要：

公式为II ##STR1## 的化合物被揭示，其中R.sup.1是一个碳氢化合物，卤代碳氢化合物，聚醚，取代苯基，取代苄基或烷基胺基; R.sup.2，R.sup.3和R.sup.4是氢，低级烷基，卤素，卤代烷基，烷氧基和类似的取代基。这些化合物在M. avium的治疗中是有用的。揭示了利用新化合物和已知化合物的方法和组合物。

公开号：

US05643912A1

点击查看最新优质反应信息

文献信息

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

申请人：Failli A. Amedeo

公开号：US20060287522A1

公开（公告）日：2006-12-21

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

这项发明提供了从式（1）中选择的吡咯苯并二氮杂吡咯烷吡啶羧酰胺，其作为卵泡刺激素受体拮抗剂。该发明还提供了利用式（1）和（2）化合物的药物组合物和治疗方法。
[EN] AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR<br/>[FR] ANTAGONISTES D'AMINO-HÉTÉROARYLE 7-HYDROXYSPIROPIPÉRIDINE INDOLINYLE DU RÉCEPTEUR P2Y1

申请人：BRISTOL MYERS SQUIBB CO

公开号：WO2014022253A1

公开（公告）日：2014-02-06

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used as medicaments.

本发明提供了如规范中定义的Formula (I)的化合物，以及包含任何此类新化合物的组合物。这些化合物是P2Y1受体的拮抗剂，可用作药物。
MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

申请人：Combs Andrew Paul

公开号：US20090286778A1

公开（公告）日：2009-11-19

The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

本发明涉及以下化学式I的大环化合物：或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction

申请人：Pfizer Inc.

公开号：US06407114B1

公开（公告）日：2002-06-18

There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

提供了式IA和式IB的化合物，其中R1、R2、R3、R4和A的含义如描述中所示，在治疗和预防需要抑制环状鸟苷3′,5′-单磷酸酯酶（例如cGMP PDE5）的医疗状况中非常有用。
[EN] PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIMIDINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

申请人：GENENTECH INC

公开号：WO2010014939A1

公开（公告）日：2010-02-04

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

揭示了公式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和其药学上可接受的盐，这些化合物在调节PIKK相关激酶信号传导方面很有用，例如mTOR，并用于治疗至少部分由PIKK信号传导途径失调引起的疾病（例如癌症）。

吡嗪-2-甲酰氯 | 19847-10-0

物质功能分类

分子结构分类

物化性质

计算性质

安全信息

SDS

反应信息

文献信息

同类化合物

相关功能分类

相关结构分类

热门分子